Search

Your search keyword '"den Hartog, Yvonne"' showing total 7 results
Start Over Author "den Hartog, Yvonne"
7 results on '"den Hartog, Yvonne"'

1. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Author

Haggenburg, Sabine, Lissenberg-Witte, Birgit I., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., de Rooij, Dennis M., van Meerloo, Johan, Cloos, Jacqueline, Kootstra, Neeltje A., Wouters, Dorine, Weijers, Suzanne S., van Leeuwen, Ester M.M., Bontkes, Hetty J., Tonouh-Aajoud, Saïda, Heemskerk, Mirjam H.M., Sanders, Rogier W., Roelandse-Koop, Elianne, Hofsink, Quincy, Groen, Kazimierz, Çetinel, Lucia, Schellekens, Louis, den Hartog, Yvonne M., Toussaint, Belle, Kant, Iris M.J., Graas, Thecla, de Pater, Emma, Dik, Willem A., Engel, Marije D., Pierie, Cheyenne R.N., Janssen, Suzanne R., van Dijkman, Edith, Poniman, Meliawati, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby, Rots, Nynke Y., Zweegman, Sonja, Kater, Arnon P., van Meerten, Tom, Mutsaers, Pim G.N.J., van Doesum, Jaap A., Broers, Annoek E.C., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2022
Full Text
View/download PDF

4. Daily pain assessment: value for nurses and patients

Author

de Rond, Marlies, de Wit, Rianne, van Dam, Frits, van Campen, Brigitte, den Hartog, Yvonne, Klievink, Rietje, Nieweg, Roos, Noort, Janny, Wagenaar, Margret, and van Campen, Barbara

Published
1999

7. Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden.

Author

Boons CCLM, den Hartog YM, Janssen JJWM, Zandvliet AS, Vos RM, Swart EL, Hendrikse NH, and Hugtenburg JG

Subjects
Adult, Aged, Area Under Curve, Drug Administration Schedule, Fasting, Female, Humans, Male, Middle Aged, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacokinetics, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrimidines pharmacokinetics, Quality of Life, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
Abstract

Objectives: Taking advantage of its food-dependent bioavailability, the present study investigated the effect of a reduced dose taken with real-life meals on the pharmacokinetics (PK) of nilotinib in chronic myeloid leukaemia (CML) patients., Methods: Nilotinib was taken fasted (300 mg BID, days 1-4) or with real-life meals (200 mg BID, days 5-11). Rich sampling (days 1, 3, 8, 11) allowed for non-compartmental PK analysis. Nilotinib exposure (AUC 0-12 h  -C min -C max ) and its intra- and interpatient variability were compared between the two regimens. Adverse events were recorded by means of a patient diary and ECG monitoring., Results: Fifteen patients aged 40-74 years participated. Nilotinib PK following 200 mg BID taken with a meal strongly resembled that of 300 mg BID taken fasted (C min percentile (P)10-P90: 665-1404 ng/mL and 557-1743 ng/mL, respectively). Meals delayed nilotinib absorption. Intra- and interpatient variability were not increased by intake with meals. Nilotinib with food was well tolerated., Conclusion: With support of therapeutic drug monitoring, the use of a reduced 200 mg nilotinib dose with real-life meals seems feasible and safe. Future (confirmatory) studies should further explore the usefulness of nilotinib dosing together with food, including the relationship with treatment efficacy as well as long-term effects on quality of life., Clinical Trial Registration: NTR5000 (Netherlands Trial Register, www.trialregister.nl)., (© 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results